ARIAD Pharmaceuticals, Inc.
| Nasdaq: ARIA
ARIAD Pharmaceuticals, Inc. operates as a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company has four products: Ridaforolimus, Ponatinib, AP1903 and AP26113. Its approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. ARIAD Pharmaceuticals was founded by Harvey J. Berger in April 1991 and is headquartered in Cambridge, MA.